Exubera inhaled insulin news and information on the FDA approved diabetes drug

• Categories:
  • Alkermes (6)
  • American Diabetes Ass’n (3)
  • Amylin Pharmaceuticals (1)
  • Apidra (1)
  • Aradigm Corp. (1)
  • Avandia (3)
  • Avandia Heart Attacks (3)
  • Avandia Injuries (3)
  • Avandia v. Exubera (3)
  • Breeze Study (6)
  • Byetta (1)
  • Diabetes Recall Alerts (2)
  • Diabetes Research (57)
  • Drug Litigation (12)
  • Eli Lilly & Co. (11)
  • Exubera - Canada (5)
  • Exubera - EU Approval (15)
  • Exubera - FDA Approval (67)
  • Exubera - Global Sales (11)
  • Exubera - India (1)
  • Exubera - Middle East (1)
  • Exubera - Nektar (59)
  • Exubera - Pfizer (172)
  • Exubera - Pulmonary Issues (75)
  • Exubera - Sales (101)
  • Exubera - Saudi Arabia (1)
  • Exubera - Spain (1)
  • Exubera - Terre Haute (1)
  • Exubera Ads (2)
  • Exubera Cost (27)
  • Exubera Education (6)
  • Exubera Layoffs (1)
  • Exubera Marketing (34)
  • Exubera News (198)
  • Exubera Risks (80)
  • Exubera: Diabetes Treatment (128)
  • Exubera: Formulary (16)
  • Exubera: Insulin & Drug Sales (107)
  • Exubera: Insurance Coverage (24)
  • Exubera: Physician Comments (39)
  • Exubera: Sanofi-Aventis (11)
  • Exubera: Smoking (9)
  • Exubera: Type 1 Diabetes (96)
  • Exubera: Type 2 Diabetes (86)
  • Generex Biotechnology Corp. (1)
  • Ind. (1)
  • Inhaled Insulin - Scotland (1)
  • Januvia - Merck (4)
  • Januvia: FDA Approval (1)
  • Lantus (1)
  • MannKind Corp. (13)
  • Novo-Nordisk (14)
  • U.K. NICE Exubea Inhaled Insulin Analysis (8)
  • Uncategorized (17)

More blogs about Diabetes, Type 1 Diabetes, Type 2 Diabetes, Insulin, Exubera, Pfizer, Nektar. Januvia

• Archives:
  • April 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • February 2006

• Search:
  
  

• Blogroll

  • Living With Diabetes
  • Scott Strumello's Weblog
  • Diabetes Mine
  • Diabetes.Blog.com

• Diabetes Drug Companies

  • Alkermes
  • Bristol-Myers Squibb
  • Eli Lilly & Co.
  • Generex Biotechnology
  • GlaxoSmithKline
  • Merck & Co., Inc.
  • Nektar
  • Novo Nordisk
  • Oramed Pharmaceuticals
  • Pfizer, Inc.
  • Sanofi Aventis

• Diabetes News

  • ADA News Updates
  • Yahoo! Diabetes News

• Get The RSS Feed

  • 
  • 
  • 
  • 
  • 
  • 
  • 
  • 
  • 
• Meta:
  • Login
  • RSS
  • Comments RSS
  • Valid XHTML
  • XFN
  • WP

  Recently Posted

  • Pfizer, Nektar: Diabetics Who Used Exubera Developed Lung Cancer
  • Pfizer Laying Off 660 Exubera Inhaled Insulin Workers From Terre Haute Plant
  • Novo-Nordisk Opts to Stop Inhaled Insulin Development
  • Novo-Nordisk, Pfizer Settle Patent Lawsuit Over Inhaled Insulin
  • Go Insulin Injectable Insulin Ads From Sanofi - Spending $1.3B in Exubera Deal Money
  • Alkeremes CEO Warns AIR Inhaled Insulin With Lilly May Affect Lung Function
  • Pfizer Stops Exubera Inhaled Insulin Sales, Citing Financial Reasons
  • Apparent Pfizer Employee Discloses Exubera Production Issues
  • Nektar's CEO: Exubera Inhaled Insulin "Not Strategically Relevant"
  • Pfizer's Senior Middle East Manager Discusses Exubera and Diabetes
  • Pharma Equity Analyst Calls Exubera a 'Sepctacular Flop'
  • Joslin Diabetics Clinic Doctor Cautions About Oral Insulin Delivery Dosing
  • Pfizer Exubera Ad, Not
  • V.A. Exubera Formulary Conditions: Strange Stuff
  • Spain's National Health System Financing Exubera for Diabetics
  • Exubera: 3rd Most 'Consumer-Friendly' Drug Name
  • Pfizer Exubera Safety Study of 2+ Years: Type 1 Diabetics
  • Canadian Health Officials Still Weighing Exubera Approval
  • Pfizer Detail Rep Appears To Have Disclosed Patient FEV Decrease, Lung Function Problems
  • Money Manager at Legg Mason Praises Mannkind's Technosphere Inhaled Insulin Device
  • Pfizer to Present at ADA Annual Scientific Sessions This Week
  • ADA President: "My Job [Is] To Talk People Out Of" Using Exubera
  • Avandia Risks v. Exubera Risks
  • Did Pfizer Spend Money On A Survey That Has Doctors Praising Exubera Inhaled Insulin?
  • NEJM Article Slams Pfizer On Exubera DTC Advertising When Drug Safety Studies Are Still Pending
  • Canadian Professor Gets Funding For Inhaled Insulin Particle Technology Research
  • Dubai Approves Exubera Inhaled Insulin
  • Pfizer Will Post 1Q Earnings Friday: Exubera Sales Expected to Underperform
  • A.G. Edwards Analyst Reports on Sluggish Exubera Sales
  • Motley Fool Compares Mannkind's Technosphere with Pfizer's Exubera Inhaled Insulin
  • Novo Nordsik Scales Back Claims Against Pfizer in Inhaled Insulin Patent Lawsuit
  • NYT Reporter Cites Analysts and Doctors in Coverage of Poor Exubera Sales
  • Diabetic Reporter Quits Using Exubera: "Blood Sugars Fluctuated Wildly"
  • Exubera Sales Totaled $18.9M in 2006 For Pfizer
  • Pfizer Exubera Inhaled Insulin Supply Far Exceeds Demand
  • Doctors and Insurers Reluctant to Approve Exubera Inhaled Insulin Scrips
  • Virginia TV Reporter Concludes Exubera is 'Gatherin Dust'
  • Diabetic Report: Exubera "Inhaler Was Large And Awkward"
  • More Complaints By A Pfizer Sales Rep Over Exubera Issues?
  • Pfizer Did Not Advertise Exubera in ADA 2007 Diabetes Resource Guide
  • Exubera Sales: Did Pfizer Fund an Advertorial in WebMD's Medscape With Misleading Information?
  • "Our Market Research...[Exubera] Profit Margins Will Greatly Overshadow" Pfizer Production Costs
  • Exubera Drug Approvals: A Global Round-Up
  • Pfizer Seeks Exubera Inhaled Insulin Launch in India
  • Nektar Reports That Exubera-Related Revenue Was $110M For 2006
  • BrandWeek Report Critiques Pfizer For 'Billion-Dollar Bong'
  • Two Year Inhaled Insulin Trial Underway, Recruiting Patients in Scotland
  • Pfizer's Exubera Inhaled Insulin Still Not Approved in Canada
  • Pfizer Launching TV Exubera Sales Campaign Targeting Diabetics
  • Drug Sales Team Message Board Post Suggests Pfizer Concerned Company Info. Being Leaked
  • NEJM Article Analyzing Pfizer's Exubera Inhaled Insulin: A Case Vignette
  • India May Get Inhaled Insulin Approval Within 2 Years
  • More Reports of Previous Exubera Inhaler Problems?
  • Study: Number of Diabetics Ineligible for Exubera Inhaled Insulin Should Double After 7 years
  • Pfizer Spokesman: No Plans to Make Protein-Based Drugs Like Exubera in Mich. Plants
  • Exubera Marketing Campaign Launched by Pfizer Using Controversial VNR's
  • Pfizer Layoffs Should Not Affect Mich. Exubera Packaging Plant
  • Pfizer Layoffs: How Much Will Drugmaker Outsource R&D?; Are Exubera Sales Hurt By Force Reduction?
  • Pfizer Closing 3 U.S. Research Sites, Slashing 10,000 Jobs; Little Mention of Exubera
  • Pfizer Exubera Manufacturing Employees Like MySpace
  • Reporter Highlights Opposition By Doctors, Diabetics to Pfizer Exubera Inhaled Insulin
  • Report: More Pfizer Layoffs Predicted, Acquisitions Anticipated
  • Study Claims Oral Insulin Delivery Achieved in Rats Using Nano-particles
  • More Competition to Pfizer's Exubera: Alkeremes and Eli Lilly & Co. Extend Inhaled Insulin Development Deal
  • Picture of Novo Nordisk AERx Inhaled Insulin: Big, Bulky Device Like Pfizer Exubera Unit
  • United Arab Emirates Gives Conditional Approval For Pfizer's Exubera
  • Diabetics Critique Exubera
  • Reporter Compares Mannkind's Technosphere To Pfizer's Exubera Inhaled Insulin
  • Reporter Says Pfizer's Exubera Sales Are "So Low" That Drugmaker Isn't Reporting Them
  • Judge Denies Novo's Attempt to Halt Pfizer's Exubera Sales, Citing Public Interest
  • Could Pfizer's Exubera Sales Force Quash The Inhaled Insulin
  • Company That Consulted For Nektar on Exubera Will Discuss Pfizer Deal
  • Researcher: Exubera May Be Effective, But Expresses "Worrisome Concern" That Exubera May Have On Lung Function
  • Nektar's 3Q Results: Heavy Reliance on Exubera Shown
  • Was a Potential Exubera Production Risk Inadvertently Disclosed?
  • Cost of Exubera Kit Reported By Nektar Investor
  • FDA Issues Alert for Counterfeit One Touch Blood Glucose Test Strips
  • UBS Analyst Cites Delayed Exubera Launch In Downgrading Pfizer, Inc.
  • Pfizer Delays Widespread Exubera Inhaled Insulin Sales, Again
  • Analysts Split on Exubera; Doctors Appear To Be The Same
  • A Diabetic Teen Critiques Exubera Inhaled Insulin from Pfizer, Inc.
  • Pfizer Profit Reported Up; Drugmaker Hopes Exubera Sales Will Increase Revenue
  • Some Pfizer Sales Reps Apparently Slamming Exubera
  • Doctors Say They Are Excited About Januvia, Others Say Existing Diabetes Drugs Already Effective
  • FDA Approval of Januvia Threatens Pfizer Exubera Inhaled Insulin Sales
  • Alcohol at Pfizer Exubera Education Event?
  • Report on Inhaled Insulin on The Market for Insulin: Is It Worth $2,100?
  • Follow-Up Re: 'Taking a Hit' For Pfizer
  • Byetta Success Suggests Needle Phobia Is Misplaced
  • Exubera Photo Shows Up on Flickr -- 'Taking a Hit' For Pfizer
  • Cleveland Clinic Doctor Concerned About Undiagnosed COPD And Exubera
  • Exubera Marketing: Are Some Pfizer Sales Reps Criticizing The Inhaled Insulin Launch?
  • Pfizer, Inc. Axes High-Level Endocrinology Marketing Executive; Exubera Affected?
  • Caution At The FDA, Or Drug Approvals As Usual?
  • Nektar Acting CEO Buys Exubera For $20 Co-Pay
  • Nektar Acting CEO Disussed Exubera At UBS Conference
  • Report: Inhaled Insulins Unlikely to Be Blockbuster Drugs
  • Pfizer, Inc. Says Exubera An "Important Source of Revenue Growth"
  • Endocrinologists Assess Exubera Inhaled Insulin at Oppenheimer Diabetes Conference
  • Univ. of Michigan Lists Pfizer, Inc.'s Exubera on Formulary List
  • Nektar CEO's One-Liner On Exubera Safety
  • Respected Health Insurance Consultant Slams Pfizer, Inc.
  • Oppenheimer Diabetes Conference Examined Exubera Inhaled Insulin
  • Exubera Formulary Doubtful: Pa. PPO and TPA Insurer
  • Pfizer's CEO Kindler Talks About Exubera at Investment Conference
  • Exubera Cost Not Covered By R.I.'s Blue Cross Blue Shield
  • Kaiser Permanente Exubera Coverage? It's Anyone's Guess
  • Follow-Up: Mannkind Corporation's Inhaled Insulin Study on Type 2 Diabetics Raises An Important Question
  • The EASD Conference: Unanswered Exubera Safety Issues
  • Pfizer, Inc. Has Exubera Inhaled Insulin Online Webcasts, But They're All Filled Up
  • Study Shows Mannkind's Technosphere Inhaled Insulin Could Threaten Pfizer, Inc.'s Exubera
  • Pfizer, Inc. Research at European Diabetes Meeting On Exubera and Type 2 Diabetics
  • Study Results of Non-Smokers Using Pfizer, Inc's Exubera After Being Exposed to Smoke
  • What Kind Of Research Are Stock Analysts Doing On Pfizer, Inc.'s Exubera?
  • Scottish Medical Group Concludes Exubera Inhaled Insulin Too Expensive For Diabetics
  • Is a Pfizer, Inc. Spokeswoman Being Straight About Exubera Inhaled Insulin?
  • WSJ Gives Pfizer, Inc. and Nektar Therapeutics Tech Award for Exubera
  • Exubera Praised By Newspaper, But Gets Cost Critique
  • Exubera Formulary: A Follow-Up
  • Exubera and Aetna, Inc. (AET): A Likely Pattern for Diabetic Insurance Coverage
  • Wall Steet Journal Article Highlights Pfizer Inc.'s Exubera Dilemma
  • Why Does A Big Mail Order Pharmacy Lack Updated Exubera Information?
  • Texas TV Station's Slick Exubera Report Sounds Like Pfizer, Inc. Spin
  • Pfizer's Exubera Launch Starts Today
  • Report Shows Pfizer, Inc. Funded Congressional Travel: An Rx For Influence?
  • Diabetics Need to Be Prepared for Disasters Like Hurricane Ernesto
  • Exubera Availability Conundrum?
  • Exubera Being Discussed at Drug Delivery Technologies and Dealmaking Conference
  • Does Pfizer, Inc. Sales Rep Fear Insurance Coverage Could Hurt Exubera?
  • Pfizer, Inc. Files a Response to Novo's Inhaled Insulin Patent Lawsuit
  • 2,300 Pfizer Sales Reps Pushing Exubera Inhaled Insulin
  • Novo-Nordisk Patent Lawsuit Against Pfizer Over Exubera
  • Despite Novo-Nordisk / Pfizer Patent Litigation, Exubera Sales Not Stopped
  • Novo Nordisk's Patent Lawsuit Against Pfizer, Inc. Over Inhaled Insulin
  • Cost of Exubera Inhaled Insulin in the U.K. Revealed
  • New Report: Inhaled Insulin Safety Concerns Affect Diabetes Drug Market
  • Doc in Exubera Study Reveals Possible Dilemma for Diabetics
  • Pfizer 'Free' Lunches and Exubera Inhaled Insulin Prescriptions
  • Is Pfizer's Exubera Insulin Delay Related to Quality Control Problems?
  • Smoking and Exubera: Some on Pfizer Sales Team Predict Problems
  • Cost of Pfizer Exubera Inhaled Insulin Revealed (Almost)
  • Pfizer Sales Rep: Exubera Will Be 'Patient-Driven'; Suggests 'Future Product Improvements'
  • Analyzing Pfizer's Delayed Exubera Inhaled Insulin Launch
  • Nektar: Pfizer's Exubera Inhaled Insulin Not Available Until Sept. 2006
  • Are Pfizer Drug Sales Reps Cynical About Exubera?
  • Pfizer Omits Important Exubera Safety Risk Info From Q2 Press Release
  • National Pharmacy Doesn't Have Exubera in Stock, Lacks Price Info
  • CBC Faux Pas Over Use of Pfizer PR Material in Exubera Report
  • Conflict? Pfizer-Funded Canadian Diabetes Doctor Touts Exubera
  • Pfizer Feels Pain of BusinessWeek Article on Exubera

June 29, 2007

Spain’s National Health System Financing Exubera for Diabetics

Filed under: Exubera News, Exubera: Diabetes Treatment, Exubera - EU Approval, Exubera - Sales, Exubera Cost, Exubera: Insurance Coverage, Exubera - Global Sales, Exubera - Spain — exuberar @ 12:11 pm

Spain’s National Health System decided to fund the cost of Exubera insulin inhalers for diabetics.

Patients will pay no more than 3€ for the Pfizer inhaled insulin, and a new report says that pharmacies in Spain now have the drug in stock.

Sphere: Related Content

Comments (0) Permalink